None listed
Conditions
Brief summary
Background: Cystic fibrosis (CF) affects gastrointestinal and lung function, nutritional status, and can interfere in swallowing. The exacerbation of the production of oxidants and the demands on antitoxic defenses lead to oxidative stress in CF patients. Objective: This study evaluated the lung function, swallowing, nutritional status, and the inflammatory and oxidative stress markers C-reactive protein (CRP), enzyme myeloperoxidase activity (MPO), nitric oxide metabolites (NOx), reduced glutathione levels (GSH), glutathione peroxidase (GPx), catalase (CAT), carbonyl protein (PC), and substances reacting to thiobarbituric acid (TBARS), associating them with the clinical condition of children and adolescents with CF. Subjects and methods: The clinical, observational study. The experimental group was formed by children and adolescents diagnosed with cystic fibrosis with impairment classified as moderate score of Schwachman-Kulczicki, clinically stable for at least thirty days prior to data collection. The control group was formed by children and adolescents without cystic fibrosis and without inflammatory symptoms, normal for weight, and paired in age and sex with the cystic fibrosis group. The lung function, swallowing, nutritional status, oxidative and inflammatory markers concentration were determined in the subjects only once. Outcome: Swallowing was not related to nutritional status; however, normal laryngeal elevation was associated with better lung function. Similarly, the absence of seriously compromised lung function was associated with satisfactory nutritional status. The appearance of systemic oxidative stress is present in patients with cystic fibrosis. The periods of bacterial infection were not determinants in the establishing and/or exacerbation of oxidative stress.
Interventions
Cystic Fibrosis is a genetic disease characterized by the secretion of thick mucus from submucosal glands. With the clogged ducts, the lungs are more susceptible to infection and inflammation. The lung disease unbalances the concentrations of oxidants and antioxidants and promotes chronic inflammation, resulting in cell damage. The overgeneration of reactive oxygen species and the depletion of antioxidants lead to oxidative stress in cystic fibrosis patients. Excessive production of reactive oxy
Cystic Fibrosis is a genetic disease characterized by the secretion of thick mucus from submucosal glands. With the clogged ducts, the lungs are more susceptible to infection and inflammation. The lung disease unbalances the concentrations of oxidants and antioxidants and promotes chronic inflammation, resulting in cell damage. The overgeneration of reactive oxygen species and the depletion of antioxidants lead to oxidative stress in cystic fibrosis patients. Excessive production of reactive oxygen species takes place principally due to abnormalities in the ion transport in the respiratory tract. Associated with this fact, it has been observed that patients with cystic fibrosis may have dysphagia, due to the relationship between swallowing and breathing, and dysphagia favors bronchospasm, pneumonia and chronic lung infections. Cross-section study for two years. In this study will be assessable association between lung function, nutritional status, swallowing and oxidative stress and inflammatory markers such as reduced glutathione (GSH), glutathione peroxidase (GPx), catalase (CAT) and activity of the myeloperoxidase enzyme (MPO), carbonyl protein (CP), thiobarbituric acid reactive substances (TBARS), nitric oxide metabolites (NOx), C-reactive protein (CRP), adenosine deaminase (ADA), tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta dosage and bacteriology of pathogenic bacteria associated to CF in children and adolescents with CF.
Sponsors
Emilia Addison Machado Moreira
Eligibility
Sex/Gender
All
Age
1 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
Experimental group: children and adolescents diagnosed with cystic fibrosis with impairment classified as moderate score of Schwachman-Kulczicki. Clinically stable for at least thirty days prior to data collection. Control group: children and adolescents without cystic fibrosis and without inflammatory symptoms, normal for weight, and paired in age and sex with the cystic fibrosis group.
Exclusion criteria
Experimental group: patients on antibiotics during or even a month before the day of collection and those in period of pulmonary exacerbation. Individuals undergoing mechanical ventilation, intubated-tracheotomised (up to 3 months before or at the time of assessment), undergoing nutritional-enteral therapy, or suffering from cerebral palsy, autism, encephalopathy, Down’s syndrome and other conditions that would compromise swallowing, in a terminal stage. Individual suffering from inflammatory (asthma, intestinal inflammatory illness, rheumatic illness), neurological or degenerative illnesses, renal insufficiency and/or diabetes mellitus, or using antibiotics and/or hormones or non-hormonal anti-inflammatory drugs, up to 6 months before the study. Control group: Individuals suffering from inflammatory (asthma, intestinal inflammatory illness, rheumatic illness), neurological or degenerative illnesses, renal insufficiency and/or diabetes mellitus, or using antibiotics and/or hormones or non-hormonal anti-inflammatory drugs, up to 6 months before the study. Individuals with symptoms of gastroesophageal reflux (heartburn, regurgitation of food, frequent cough).
Outcome results
None listed